REGORAFENIB News

REGORAFENIB currently has 8 news articles, with 19 predicted indications.

This page combines the AI-predicted indications for REGORAFENIB with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Evidence level: L5
Predicted indications (19):
- adenocarcinoma of liver and intrahepatic biliary tract (99.0%)
- liver cancer (99.0%)
- squamous cell carcinoma of liver and intrahepatic biliary tract (99.0%)
- hepatocellular carcinoma (99.0%)
- pediatric hepatocellular carcinoma (99.0%)
- gastrointestinal stromal tumor (99.0%)
- metastasis from malignant tumor of colon (99.0%)
- fibrolamellar hepatocellular carcinoma (99.0%)
- undifferentiated carcinoma of liver and intrahepatic biliary tract (99.0%)
- liposarcoma (99.8%)
- ovarian myxoid liposarcoma (99.7%)
- clear cell renal carcinoma (99.5%)
- renal cell carcinoma associated with neuroblastoma (99.2%)
- unclassified renal cell carcinoma (99.2%)
- renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions (99.2%)
- childhood kidney cell carcinoma (99.1%)
- vulva sarcoma (99.1%)
- spindle cell liposarcoma (98.8%)
- renal cell carcinoma (disease) (98.7%)